Therefore, ES clusters may provide a reference in the development and selection of specific chemotherapeutic targets in CCA, such as therapies targeting ERBB2/HER2 signaling (54), IDH inhibitors (ClinicalTrials.gov identifier: NCT02073994) and RGFR-targeting agents (55). This evidence concerns the gene ERBB2 and cholangiocarcinoma.